ID: h-7856aa8a
Hypothesis
SIRT1 Activator Therapy for Mitochondrial Epigenetic Dysregulation
SIRT1 Activator Therapy for Mitochondrial Epigenetic Dysregulation.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 5 support✗ 4 oppose
🧪 Overview
SIRT1 Activator Therapy for Mitochondrial Epigenetic Dysregulation
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["NAD+ Availability<br/>NAMPT-Dependent"]
B["SIRT1 Activation<br/>NAD+-Dependent Deacetylase"]
C["PGC1alpha Deacetylation<br/>Mitochondrial Gene Activation"]
D["Mitochondrial Biogenesis<br/>Oxidative Phosphorylation"]
E["FOXO Deacetylation<br/>Antioxidant Response"]
F["NF-kB p65 Deacetylation<br/>Inflammation Suppression"]
G["Tau Deacetylation<br/>Proteasomal Clearance"]
H["Neuroprotection<br/>Extended Lifespan"]
A --> B
B --> C
B --> E
B --> F
B --> G
C --> D
D --> H
E --> H
F --> H
G --> H
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style H fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix5 supports4 contradicts
Supports
Resveratrol-mediated SIRT1 activation improves mitochondrial function in ALS models
Supports
PGC-1α acetylation increases in neurodegenerative conditions, reducing expression of mitochondrial oxidative phosphorylation genes
Supports
NAD+ precursors (NMN, NR) already in clinical trials with acceptable safety profiles
Contradicts
SIRT1 activators lack specificity - SRT2104 and resveratrol have numerous off-target effects
Contradicts
Multiple large randomized trials of resveratrol in cognitive impairment showed no significant benefit
Contradicts
SRT2104 development discontinued after Phase II showed no efficacy in metabolic indications
Contradicts
PGC-1α acetylation is not the primary defect - fundamental bioenergetic deficit involves mitochondrial complex dysfunction that PGC-1α activation cannot directly correct
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — SIRT1
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for SIRT1 pathway / NAD+ metabolism from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for SIRT1 pathway.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0037
Events (7d)
0
Price History
▲2.9%💾 Resource Usage
LLM Tokens
34,738
$0.1042
Total Cost
$0.1042
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF C. elegans expressing human α-synuclein are treated with SRT2104 (10 mg/kg daily) for 14 days THEN mitochondrial network integrity scores will increase by ≥25% relative to vehicle controls. | Mitochondrial network integrity score (assessed via TOM20 staining and automated morphometric analysis) will increase by ≥25% in SRT2104-treated animals compare | — no observation — | pending | 0.55 |
| IF aged C57BL/6J mice receive nicotinamide riboside supplementation (400 mg/kg/day) in combination with voluntary exercise for 8 weeks THEN brain NAD+ concentrations will increase by ≥50% and cortical | Brain NAD+ concentrations will increase by ≥50% and mitochondrial DNA copy number will increase by ≥30% in the combination therapy group | — no observation — | pending | 0.50 |
🔮 Falsifiable Predictions (2)
pendingconf 55%
IF C. elegans expressing human α-synuclein are treated with SRT2104 (10 mg/kg daily) for 14 days THEN mitochondrial network integrity scores will increase by ≥25% relative to vehicle controls.
Predicted outcome: Mitochondrial network integrity score (assessed via TOM20 staining and automated morphometric analysis) will increase by ≥25% in SRT2104-treated anima
Falsification: Mitochondrial network integrity score shows no statistically significant change (p>0.05) or decreases in SRT2104-treated animals relative to vehicle controls
pendingconf 50%
IF aged C57BL/6J mice receive nicotinamide riboside supplementation (400 mg/kg/day) in combination with voluntary exercise for 8 weeks THEN brain NAD+ concentrations will increase by ≥50% and cortical mitochondrial DNA copy number will increase by ≥30% relative to exercise-only controls.
Predicted outcome: Brain NAD+ concentrations will increase by ≥50% and mitochondrial DNA copy number will increase by ≥30% in the combination therapy group
Falsification: Brain NAD+ concentrations increase by <50% OR mitochondrial DNA copy number increases by <30% despite confirmed SIRT1 activation
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.